Boston Scientific (BSX) Stock Movement Summary Boston Scientific reported Q4 2025 earnings that beat Wall Street expectations, with non-GAAP profit of $0.80 per share (2.4% above consensus) and Q4 sales of $5.29 billion, up 15.9% year-over-year. The company's cardiovascular and MedSurg units showed strong performance. However, the company issued 2026 guidance that disappointed investors. Boston Scientific projected 2026 revenue growth between 10.5% and 11.5%, with adjusted earnings per share of $3.00, described as below Wall Street expectations. Q1 2026 revenue was forecast at approximately $5.19 billion. Following the guidance announcement on February 4, 2026, BSX shares fell sharply, declining between 11% and 13.9% in trading. The electrophysiology segment, which grew 37% year-over-year in Q4, showed flat U.S. quarter-over-quarter growth, raising analyst concerns.
Read full analysisBoston Scientific (BSX) Stock Movement Summary Boston Scientific reported Q4 2025 earnings that beat Wall Street expectations, with non-GAAP profit of $0.80 per share (2.4% above consensus) and Q4 sales of $5.29 billion, up 15.9% year-over-year. The company's cardiovascular and MedSurg units showed strong performance. However, the company issued 2026 guidance that disappointed investors. Boston Scientific projected 2026 revenue growth between 10.5% and 11.5%, with adjusted earnings per share of $3.00, described as below Wall Street expectations. Q1 2026 revenue was forecast at approximately $5.19 billion. Following the guidance announcement on February 4, 2026, BSX shares fell sharply, declining between 11% and 13.9% in trading. The electrophysiology segment, which grew 37% year-over-year in Q4, showed flat U.S. quarter-over-quarter growth, raising analyst concerns.
Boston Scientific Corporation (BSX) is a publicly traded company in the Healthcare sector.